There are currently 1330 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Atlanta, Georgia
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
A Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Healthy Participants and in Participants With CF
NCT06237335
Recruiting
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/29/2025
Locations: Emory University, Atlanta, Georgia
Conditions: Cystic Fibrosis
Register for Updates
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725
Recruiting
This study will monitor patients during the first year following their stroke. Stroke is a very serious condition where there is a sudden interruption of blood flow in the brain. The main aim of the study will be to find out how many of those who experience their first-ever stroke then go on to develop spasticity that would benefit from treatment with medication. Spasticity is a common post-stroke condition that causes stiff or ridged muscles. The results of this study will provide a standar... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/29/2025
Locations: Emory University Merge, Atlanta, Georgia
Conditions: Spasticity as Sequela of Stroke
Register for Updates
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
NCT06315751
Recruiting
This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will be enrolled after a sentinel cohort of adults is complete.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Noema TTS-201 Site #79, Atlanta, Georgia
Conditions: Tourette Syndrome
Register for Updates
Post Market Evaluation of Clinical Safety and Performance of the Fitbone Transport and Lengthening System
NCT06400732
Recruiting
This is an open-label, prospective, observational, post-market, uncontrolled, multi-center study intended to evaluate the safety and clinical performance of the FITBONE Transport and Lengthening Nail when used according to the manufacturer's Instructions for Use. The FITBONE Transport \& Lengthening Nail is a variant of the FITBONE TAA Nail, which has been commercially available in the US since 2017. The clinical performance and safety of the medical device have been assessed based on mechanical... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Emory University School of Medicine / Grady Memorial Hospital, Atlanta, Georgia
Conditions: Fractures, Bone, Fractures, Closed, Fractures, Open, Fracture of Femur, Fracture Nonunion, Fracture of Tibia, Limb Deformity, Limb Fracture, Limb Defect, Limb Asymmetry
Register for Updates
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401
Recruiting
This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Neurocrine Clinical Site, Atlanta, Georgia
Conditions: Major Depressive Disorder
Register for Updates
RADIQAL Study (Radiation Dose and Image Quality Trial)
NCT06944509
Recruiting
The Azurion R4.0 is developed by Philips Medical Systems Nederland B.V., a Philips Healthcare company. The Azurion is an interventional X-ray system which is used for live X-ray imaging during invasive cardiac procedures. The proposed Azurion R4.0 includes new x-ray image postprocessing (Xres5) compared to its predecessor, which was equipped with ClarityIQ image post-processing (Xres4). Azurion R4.0 is a cleared device for EU-MDR regulated countries, submission for FDA510K clearance in the US i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Coronary Artery Disease
Register for Updates
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927
Recruiting
The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Piedmont Cancer Institute, Atlanta, Georgia +1 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Register for Updates
GEMINI-NSCLC: NSCLC Biomarker Study
NCT05236114
Recruiting
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Morehouse School of Medicine (MSM), Atlanta, Georgia +1 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
NCT05137054
Recruiting
This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior therapies and needed to be treated again. In the initial study, some participants treated with linvoseltamab had improvement of their myeloma, including complete responses (no evid... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Multiple Myeloma
Register for Updates
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277
Recruiting
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: Emory University School of Medicine, Atlanta, Georgia +1 locations
Conditions: Lupus Nephritis
Register for Updates
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
NCT05433142
Recruiting
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Winship Cancer Institute of Emory University, Atlanta, Georgia
Conditions: Clear Cell Renal Cell Carcinoma
Register for Updates